If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Biotricity, Inc. (BTCY)

Price chart

Return from IPO

Company News

IPO Profile

About company

(Note: IPOScoop has No Call on this offering, which is NOT an IPO. This deal is an uplift to the NASDAQ from the OTCQB where the stock had also traded under the symbol “BTCY”.)Biotricity is a leading-edge medical technology company focused on biometric data monitoring solutions. Their aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. They approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. They believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue. In post-diagnostic markets, they intend to apply medical grade biometrics to enable consumers to self-manage, thereby driving patient compliance and reducing healthcare costs. Their first focus is on the multi-billion-dollar diagnostic mobile cardiac telemetry market, otherwise known as MCT.They developed their FDA-approved Bioflux® MCT technology, comprised of a monitoring device and software components, which they made available to the market under limited release on April 6, 2018, in order to assess, establish and develop sales processes and market dynamics. The fiscal year ended March 30, 2020 marked the Company’s first year of expanded commercialization efforts, focused on sales growth and expansion. They have expanded their sales efforts to 23 states, with the intention to expand further and compete in the broader US market using an insourcing business model. Their technology has a large potential total addressable market, which can include hospitals, clinics and physicians’ offices, as well as independent diagnostic testing facilities (or IDTFs). They believe their solution’s insourcing model, which empowers physicians with state-of-the-art technology and charges technology service fees for its use, has the benefit of a reduced operating overhead for the Company, and enables a more efficient market penetration and distribution strategy. This, when combined with the value of the Company’s solution in the diagnosis of cardiac arrhythmias, enhancement of patient outcomes, improved patient compliance, and the corresponding reduction of healthcare costs, is what they believe is driving growth and increasing revenue.Note: As of June 30, 2021, they had an accumulated deficit of $68,715,051.*Note: Financial statements were not available. 
Medical Technology
Employees Founded


Address: 275 Shoreline Drive, Redwood City, California

Telephone: (800) 590-4155

Web page:

IPO information

First Trade Date 8/26/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5
Shares Revised (MM) 5
Expected offer amount (MM) $15
Realized offer amount(MM) $15

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $
Net Income (Loss) (MM) $


What do you think will happen with the BTCY share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: H.C. Wainwright & Co.

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
H.C. Wainwright & Co.

Tweets about $BTCY

Tweets volume:

RT volume:


Google Trends Stats